1. P640: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN COMBINATION WITH VENETOCLAX±RITUXIMAB IN RELAPSED/REFRACTORY CLL: RESULTS FROM THE BRUIN PHASE 1B STUDY. (23rd June 2022) Authors: Roeker, L. E.; Mato, A. R.; Brown, J. R.; Coombs, C. C.; Shah, N. N.; Wierda, W. G.; Patel, M. R.; Lewis, K. L.; Balbas, M.; Zhao, J.; Ku, N. C.; Kherani, J. F.; Tsai, D. E.; Nair, B.; Cheah, C. Y. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 538 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR'S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS). (23rd June 2022) Authors: Sharman, J. P.; Jurczak, W.; Coombs, C. C.; Hill, M.; Wang, D.; Ku, N. C.; Guntur, A.; Shahda, S.; Leow, C. C.; Ghia, P.; Mato, A. R. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1744 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗